Clinical trials: Irritation
Irritable Bowel Syndrome with Diarrhea
Efficacy and Safety of Changkang Granule in the Treatment of Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)
The aim of this study is to evaluate the efficacy and safety of Changkang granule as compared to placebo over a 8-week treatment period and explore TCM syndrome types.
- Trial name
- NCT04492787
- Testing
- Changkang Granule
- Where
- 8 sites in China
- Volunteers
- 240 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Irritable Bowel Syndrome (IBS), Irritable Bowel Syndrome of Diarrhea Type (IBS-D)
Gelsectan® in the Treatment of Patients With Diarrhoea-predominant Irritable Bowel Syndrome
Irritable Bowel Syndrome (IBS) is one of the major Disorders of Gut-Brain Interaction (DGBI) and the most frequent reasons for referral to both primary care providers and gastroenterologists.IBS is not a life-threatening disease…
- Trial name
- GIANT (NCT06681012)
- Testing
- Gelsectan®
- Where
- 12 sites in Belgium, France and 2 more
- Volunteers
- 330 people
- Sponsor
- Devintec Sagl
Injection Site Irritation, Injection Site Bruising
Comparison of Subcutaneous Injection of Normal Saline and Bacteriostatic Saline
This is a randomized, double-blind, single-center clinical trial comparing normal saline and bacteriostatic saline subcutaneous injection within a single subject.
- Conditions
- Injection Site Irritation, Injection Site Bruising, Injection Site Discomfort, Benzoic Acid Adverse Reaction
- Trial name
- NCT05109000
- Testing
- Sodium Chloride 0.9% Inj, Bacteriostatic Sodium Chloride 0.9 % INJECTION VIAL (ML)
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Jeffrey Alan Klein, MD
Irritable Bowel Syndrome
Effect of Duolac 7S Administration on Improving Symptom in Irritable Bowel Syndrome
Gut microflora-mucosal interactions may be involved in the pathogenesis of irritable bowel syndrome (IBS). The purpose of this study is to investigate the efficacy of Duolac7S in changing the colonic microflora and improve the…
- Trial name
- NCT01088971
- Testing
- Duolac7S, starch
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Cell Biotech Co., Ltd.
Healthy Volunteers
Cumulative Irritation Potential of 828 Ointment
Cumulative Irritation Patch Test
- Trial name
- NCT00767455
- Testing
- HP828-101
- Where
- United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Healthpoint
Irritable Bowel Syndrome
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
The primary objectives of this study are to explore the therapeutic effect of eluxadoline in treating irritable bowel syndrome with diarrhea (IBS-D) in pediatric participants 6-17 years of age, to evaluate the pharmacokinetics of…
- Trial name
- NCT03339128
- Testing
- Eluxadoline
- Where
- 46 sites in United States, Bulgaria and 7 more
- Volunteers
- 272 people
- Sponsor
- AbbVie
Irritable Bowel Syndrome
A Trial for New Treatment of Adult Participants With Irritable Bowel Syndrome
A study to evaluate the effectiveness of oral doses of Blautix in adult participants with irritable bowel syndrome (IBS).
- Trial name
- NCT03721107
- Testing
- Blautix
- Where
- 34 sites in United States, Ireland and 1 more
- Volunteers
- 366 people
- Sponsor
- 4D pharma plc
Skin Care
To Investigate Primary Irritation Potential of Four Skin Serum Products on Human Subjects Assessed by 24 Hour Patch Test
To assess the irritation potential of four prototype daily defense serum formulations after 24 (± 2) hours under semi-occlusive patch application to the skin of healthy volunteers.
- Trial name
- NCT03233009
- Testing
- Experimental Daily Defense Serum A, Experimental Daily Defense Serum C, Experimental Daily Defense Serum G
- Where
- 2 sites in Brazil
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Skin Manifestations
Standard TDS Irritation Study: Trained Skin Grader vs. Digital Imaging
The purpose of this study is to (1) collect trained observer scores and digital images of skin irritated by generic and RLD Lidocaine 5% delivered via TDS, and (2) assess performance of an automated system for predicting scores…
- Trial name
- TDS_TSG_DI (NCT02787356)
- Testing
- TDS Lidocaine 5%; generic, TDS Lidocaine 5%; RLD
- Volunteers
- healthy volunteers welcome
- Sponsor
- SRI International
Autistic Disorder
An Evaluation of Low Level Laser Light Therapy for Autistic Disorder
The purpose of this study is to determine whether the Erchonia HLS Laser is effective in the treatment of irritability associated with autistic disorder in children and adolescents aged five (5) to seventeen (17) years.
- Trial name
- NCT03379662
- Testing
- Erchonia HLS Laser
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- Erchonia Corporation
Diarrhea-Predominant Irritable Bowel Syndrome
Study to Assess Effects of Postbiotic vs Placebo in Participants With Diarrhea-predominant IBS
The present study is a randomized, double-blind, placebo-controlled, parallel group clinical study that assesses the effect of postbioc on the complaints of subjects with moderate to severe diarrhoea-predominant irritable bowel…
- Trial name
- NCT06346847
- Testing
- Postbiotic
- Where
- 23 sites in India
- Volunteers
- 384 people, healthy volunteers welcome
- Sponsor
- A-Mansia Biotech S.A.
Hygiene
Topic Compatibility Dermacyd Wipes - Lactoserum - Hygiene
The purpose of this study is to demonstrate the absence of irritation potential (primary dermic irritability and cumulated dermic irritability) and allergy (sensibilization) of the product Dermacyd wipes.
- Trial name
- NCT00371852
- Testing
- lactoserum
- Where
- Brazil
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Sanofi
Irritable Bowel Syndrome
Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome
This is placebo-controlled study of three rifaximin doses in patients with DIBS. Subjects will be randomized to receive daily doses of placebo BID, rifaximin 275 mg BID, rifaximin 550 mg BID, or 1100 mg BID for 14 days.
- Trial name
- NCT00269412
- Testing
- Rifaximin
- Where
- 67 sites in United States
- Volunteers
- 525 people
- Sponsor
- Bausch Health Americas, Inc.
Irritable Bowel Syndrome
A Study of BMS-562086 in Patients With Irritable Bowel Syndrome
The primary purpose of this study is to evaluate the effects of BMS-562086 on small bowel and colonic transits in female subjects with diarrhea-predominant irritable bowel syndrome (D-IBS)
- Trial name
- NCT00399438
- Testing
- BMS-562086
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Bristol-Myers Squibb
Autism Spectrum Disorders
Open-Label Study of the Safety and Tolerability of STX209 in Subjects With Autism Spectrum Disorders
The study objective is to explore the safety and tolerability of STX209 in subjects with Autism Spectrum Disorders and to obtain preliminary data on several measures of efficacy in treating irritability.
- Trial name
- NCT00846547
- Testing
- Arbaclofen
- Where
- 8 sites in United States
- Volunteers
- 32 people
- Sponsor
- Seaside Therapeutics, Inc.
Irritable Bowel Syndrome Characterized by Constipation
A Study of the Effect of Linaclotide on Abdominal Girth in Participants With Irritable Bowel Syndrome With Constipation (IBS-C)
The objective of this trial is to determine the effect of linaclotide on abdominal girth in IBS-C participants with the baseline symptoms of abdominal bloating and an increased abdominal girth.
- Trial name
- NCT02837783
- Testing
- Linaclotide
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Irritable Bowel Syndrome, IBS - Irritable Bowel Syndrome
Human Milk Oligosaccharides (HMOs) for Irritable Bowel Syndrome (IBS)
To assess the effects of a Human Milk Oligosaccharide mix given once daily for 12 weeks on stool consistency and abdominal pain compared to placebo in individuals with Irritable Bowel Syndrome (IBS).
- Trial name
- HIBS (NCT05205785)
- Testing
- Human Milk Oligosaccharide Mix
- Where
- Ireland
- Volunteers
- 204 people
- Sponsor
- dsm-firmenich Switzerland AG
Irritable Bowel Syndrome
Ibodutant for Relief of Irritable Bowel Syndrome (IRIS)
The purpose of the study is to evaluate the benefit of treatment with oral dose of Ibodutant (code: MEN 15596) on IBS symptoms and the safety and tolerability of this therapy.
- Trial name
- IRIS (NCT00761007)
- Testing
- Ibodutant
- Where
- 6 sites in Denmark, Germany and 4 more
- Volunteers
- 554 people
- Sponsor
- Menarini Group
Constipation Predominant, Irritable Bowel Syndrome (IBS-C)
The Effect of Tegaserod on Patterns of Flow in the Small Bowel of Patients With Irritable Bowel Syndrome (IBS)
Evaluation of the effect of tegaserod treatment on small intestinal motility and flow pattern in female IBS-C patients.
- Trial name
- NCT00171431
- Testing
- Tegaserod
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
Sunburn
Dermal Irritation, Sensitization and Cumulative Irritation Potential of 6% Bemotrizinol
The purpose of this clinical trial is to evaluate the dermal safety of Bemotrizinol (6%).
- Trial name
- NCT05260359
- Testing
- 6% Bemotrizinol (BEMT) in a basic sunscreen oil formulation, 6% Bemotrizinol (BEMT) dispersion in petrolatum, Sunscreen oil vehicle with 10% ethanol as penetration enhancer without BEMT
- Where
- United States
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- dsm-firmenich Switzerland AG